---
layout: default
title: Lenograstim
parent: 僅模型預測 (L5)
nav_order: 75
evidence_level: L5
indication_count: 4
---

# Lenograstim
{: .fs-9 }

證據等級: **L5** | 預測適應症: **4** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Lenograstim (DB13144): Drug Repurposing Evaluation — Insufficient Data to Complete Analysis

## One-Sentence Summary

Lenograstim (DrugBank ID: DB13144) is a recombinant human granulocyte colony-stimulating factor (G-CSF) currently **not approved or marketed in Taiwan**.
The TxGNN model has **not returned any predicted new indications** for this drug in the current Evidence Pack.
Without prediction output, original indication data, or safety information, a complete repurposing evaluation cannot be generated at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available |
| Predicted New Indication | Not available — no TxGNN predictions returned |
| TxGNN Prediction Score | Not available |
| Evidence Level | N/A |
| Taiwan Market Status | ✗ Not marketed (0 authorizations) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why This Prediction Cannot Be Assessed

The `predicted_indications` array in the Evidence Pack is empty, meaning the TxGNN model did not return any candidate indications for Lenograstim during this pipeline run. This may occur for one of the following reasons:

- The drug node was not present or sufficiently connected in the knowledge graph used for prediction.
- The prediction score for all candidate diseases fell below the reporting threshold.
- The pipeline run for this drug was incomplete or interrupted.

Additionally, the mechanism of action (MOA) data is missing (recorded as a High-severity data gap), which would normally anchor the mechanistic reasoning section. Without both a TxGNN prediction and MOA data, it is not possible to assess biological plausibility for any new indication.

From publicly available pharmaceutical sources, Lenograstim is known to be a glycosylated recombinant form of human G-CSF. However, injecting external knowledge to fabricate a repurposing case in the absence of model output would not be appropriate in this evaluation framework.

---

## Taiwan Market Information

Lenograstim is currently **not approved or marketed in Taiwan**. No TFDA product licenses are on record.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|----------------------|--------------|-------------|---------------------|
| — | — | — | No records found |

---

## Safety Considerations

Please refer to the package insert for safety information.

> Note: Both key warnings and contraindications were identified as data gaps in this Evidence Pack. Drug interaction records were also not found in the DDI query (status: `not_found`).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack does not contain the minimum required inputs — predicted indications, original indication text, or safety data — needed to generate a valid repurposing evaluation. Proceeding without these elements would produce an unreliable report.

**To proceed, the following is needed:**

- [ ] **TxGNN prediction re-run**: Verify the drug node for `DB13144` exists in the knowledge graph and re-execute the prediction pipeline; investigate why no indications were returned
- [ ] **Original indication data**: Retrieve approved indication(s) from TFDA package insert PDF or DrugBank entry
- [ ] **Mechanism of action (MOA)**: Query DrugBank API for DB13144 pharmacodynamics and target information
- [ ] **Safety data**: Parse TFDA package insert for warnings, contraindications, and special population guidance
- [ ] **DDI data**: Expand DDI query to include synonyms (e.g., "Granocyte", "G-CSF", "r-HuG-CSF") to confirm no interactions exist or retrieve relevant ones
- [ ] **Market context**: Confirm whether Lenograstim is approved in EMA/FDA jurisdictions, as this could supplement the Taiwan-absent regulatory context
## Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning.
Klinisk validering krävs före klinisk tillämpning.

---

